Problem

Invert addresses the information bottleneck in bioprocess development and manufacturing. Bioprocesses combine complex, high-volume data from instruments, historians, ELNs, MES platforms, online time-series feeds, offline samples, and downstream analytics, yet that information is often fragmented and difficult to contextualize. The result is that scientists and manufacturing teams spend substantial time assembling, reconciling, and cleaning data rather than interpreting it; process characterization depends on cross-batch comparisons and traceability, while a single fed-batch run can generate weeks of online data plus daily measurements and product-quality results.

The economics are especially painful during scale-up, CMC development, and digital-twin programs. Invert cites an in-house alternative costing $200,000–$400,000, taking 12–18 months, and requiring engineering resources that teams may not have. Its clearest use case is turning disconnected run data into a reliable, analysis-ready foundation for process characterization and optimization—for example, closing an Ambr250 data gap so a $2 million-plus digital twin can operate with real-time data, or eliminating thousands of hours of manual data work across a biologics program.

Product / Service

Invert sells a bioprocess-native software platform that connects equipment and data sources across process development and manufacturing. It is vendor-agnostic, offering pre-built connectivity to systems and equipment from vendors such as Sartorius, Eppendorf, Cytiva, DeltaV, and OSIsoft. The platform ingests online and offline data, automatically links it to the relevant batch or run, harmonizes parameters and units, and provides a centralized, batch-centric data layer without requiring customers to replace their existing systems. For on-site equipment, Invert also supports secure edge-based data collection and protocols such as OPC-UA and OPC-DA.

On top of that foundation, Invert provides data-quality monitoring, live-run visibility, analytics, predictive and hybrid process modeling, and Invert Assist, an AI interface that lets users analyze data and model processes with natural-language prompts. Assist produces inspectable, reproducible Python code rather than opaque answers, supporting auditability in regulated environments. The intended benefit is faster scientific decision-making, fewer manual data-pull and reconciliation tasks, earlier detection of missing or inconsistent data, and an AI-ready data environment that can support scale-up, tech transfer, quality control, and manufacturing optimization.

Market

Invert competes in bioprocess data analytics, bioprocess intelligence, and AI software for biomanufacturing. Its initial customer focus was bio-industrial companies producing products in bioreactors, while its current positioning targets biopharma, biologics CDMOs, cell-therapy companies, process-development teams, MSAT groups, and pharmaceutical manufacturers. The competitive set includes broad scientific-data platforms and established bioprocess informatics systems; Invert’s own comparison names Bioraptor and Genedata, positioning Bioraptor as a general scientific data and machine-learning platform and Genedata as a broader enterprise system that can require substantial customization.

The evidence indicates that Invert is operating commercially rather than being merely pre-revenue. Its official case studies describe cell-therapy, biologics, and CDMO teams using the platform in production, including claims of 3,000-plus FTE hours recovered per program, $400,000 of integration costs avoided, and deviations closed in days instead of weeks. Third-party company profiles report approximately $20.6 million raised, and one third-party estimate put 2024 revenue at $5 million; the exact revenue figure is not independently verified in the available evidence, but the production deployments, named use cases, and funding provide clear evidence of early commercial traction.